Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women.

ABSTRACT:

Background

The prevalence of pre-treatment drug resistance (PDR) to non-nucleoside reverse-transcriptase inhibitor (NNRTI) agents is increasing in sub-Saharan Africa, which may decrease the effectiveness of efavirenz-based antiretroviral therapy (ART) programs. However, due to recent safety concerns, there has been hesitancy to replace efavirenz-based ART with dolutegravir in women of reproductive potential. Our objective was to evaluate whether PDR testing for women not initiating dolutegravir-based ART would be a cost-effective strategy to address the challenges posed by PDR.

Methods

We developed an HIV drug resistance model that simulates the emergence and transmission of resistance mutations, calibrated to the Kenyan epidemic. We modeled three care strategies for PDR tes

SUBMITTER: Duarte HA 

PROVIDER: S-EPMC7256304 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature